3
-Substituted-6-substituted-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxyl
ic acid
    4.
    发明授权
    3 -Substituted-6-substituted-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxyl ic acid 失效
    3-取代的6-取代-7-氧代-1-氮杂双环[3.2.0]庚-2-烯-2-羧酸

    公开(公告)号:US4347368A

    公开(公告)日:1982-08-31

    申请号:US207042

    申请日:1980-11-14

    摘要: Disclosed are 3- and 6-substituted 7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acids having the structure: ##STR1## wherein R.sup.6, R.sup.7 and R.sup.8 are, inter alia, independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl and aralkyl. Such compounds as well as their pharmaceutically acceptable salt, ester and amide derivatives are useful as antibiotics. Also disclosed are processes for the preparation of such compounds, pharmaceutical compositions comprising such compounds and methods of treatment comprising administering such compounds and compositions when an antibiotic effect is indicated.

    摘要翻译: 公开了具有以下结构的3-和6-取代的7-氧代-1-氮杂双环[3.2.0]庚-2-烯-2-羧酸:其中R6,R7和R8特别独立地选自 由氢,烷基,烯基,芳基和芳烷基组成的组。 这些化合物及其药学上可接受的盐,酯和酰胺衍生物可用作抗生素。 还公开了制备这些化合物的方法,包含这些化合物的药物组合物和治疗方法,包括当指出抗生素作用时施用这些化合物和组合物。

    (-)(Cis-1,2-epoxy propyl)phosphonic acid amides
    5.
    发明授权
    (-)(Cis-1,2-epoxy propyl)phosphonic acid amides 失效
    ({31}(顺式-1,2-环氧丙基)膦酸酰胺

    公开(公告)号:US3943153A

    公开(公告)日:1976-03-09

    申请号:US848678

    申请日:1969-08-08

    CPC分类号: C07F9/65848 C07F9/65505

    摘要: Amides and thioates of (-)(cis-1,2-epoxypropyl)-phosphonic acid and phosphonothioic acid are prepared by converting (-)(cis-1,2-epoxypropyl)phosphonic acid or phosphonothioic acid or a salt thereof to an acid halide and reacting the acid halide with an amine, and by reacting the phosphonic acid or a salt thereof with an amine in the presence of a carbodiimide. The novel (-)(cis-1,2-epoxypropyl)phosphonic and phosphonothioic amides are active antibacterial agents.

    摘要翻译: ( - )(顺式-1,2-环氧丙基) - 膦酸和膦酰硫酸的酰胺和硫酸盐是通过将( - )(顺式-1,2-环氧丙基)膦酸或硫代磷酸或其盐转化成酸 卤化物并使酰卤与胺反应,并在碳二亚胺存在下使膦酸或其盐与胺反应。 新型( - )(顺式-1,2-环氧丙基)膦酸和膦酰基酰胺是活性抗菌剂。

    3-Substituted
thio-6-amido-7-oxo-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid
s-oxides
    7.
    发明授权
    3-Substituted thio-6-amido-7-oxo-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid s-oxides 失效
    3-取代的硫代-6-氨基-7-氧代-1-氮杂双环[3.2.0] - 庚-2-烯-2-羧酸S-氧化物

    公开(公告)号:US4277482A

    公开(公告)日:1981-07-07

    申请号:US84934

    申请日:1979-10-15

    CPC分类号: C07D477/24

    摘要: Disclosed are S-oxides of 3-substituted thio-6-amido-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acids having the structure: ##STR1## wherein: n is 1 or 2; R.sup.1 is hydrogen or acyl; and R.sup.8 is, inter alia, independently selected from the group consisting of alkyl, alkenyl, aryl and aralkyl. Such compounds as well as their pharmaceutically acceptable salt, ester and amide derivatives are useful as antibiotics. Also disclosed are processes for the preparation of such compounds, pharmaceutical compositions comprising such compounds and methods of treatment comprising administering such compounds and compositions when an antibiotic effect is indicated.

    摘要翻译: 公开了具有以下结构的3-取代的硫代-6-氨基-7-氧代-1-氮杂双环[3.2.0]庚-2-烯-2-羧酸的S-氧化物:其中:n是1或 2; R1是氢或酰基; 并且R8特别地独立地选自烷基,烯基,芳基和芳烷基。 这些化合物及其药学上可接受的盐,酯和酰胺衍生物可用作抗生素。 还公开了制备这些化合物的方法,包含这些化合物的药物组合物和治疗方法,包括当指出抗生素作用时施用这些化合物和组合物。

    2-, 5-, and 6-Substituted-1-carbadethiapen-2-em-3-carboxylic acids
    8.
    发明授权
    2-, 5-, and 6-Substituted-1-carbadethiapen-2-em-3-carboxylic acids 失效
    2-,5-和6-取代的1-碳氮杂环戊烯-2-烯-3-羧酸

    公开(公告)号:US4269873A

    公开(公告)日:1981-05-26

    申请号:US60552

    申请日:1979-07-25

    摘要: Disclosed are 2-, 5- and 6-substituted-1-carbadethiapen-2-em-3-carboxylic acids having the structure: ##STR1## wherein R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are, inter alia, independently selected from the group consisting of hydrogen, (R.sup.9 is not hydrogen), alkyl, alkenyl, aryl and aralkyl. Such compounds, as well as their pharmaceutically acceptable salt, ester and amide derivatives, are useful as antibiotics. Also disclosed are processes for the preparation of such compounds and methods of treatment comprising administering such compounds and compositions when an antibiotic effect is indicated.

    摘要翻译: 公开了具有以下结构的2-,5-和6-取代-1-碳代二脱氧-2-烯-3-羧酸:其中R 6,R 7,R 8和R 9特别地独立地选自 由氢,(R9不是氢),烷基,烯基,芳基和芳烷基组成。 这些化合物及其药学上可接受的盐,酯和酰胺衍生物可用作抗生素。 还公开了制备这些化合物的方法和治疗方法,包括当指示抗生素效果时施用这些化合物和组合物。

    2-carbamimidoyl-6-substituted-1-carbadethiapen-2-em-3-carboxylic acids
    9.
    发明授权
    2-carbamimidoyl-6-substituted-1-carbadethiapen-2-em-3-carboxylic acids 失效
    2-甲脒基-6-取代-1-碳代二烯-2-烯-3-羧酸

    公开(公告)号:US4997936A

    公开(公告)日:1991-03-05

    申请号:US898887

    申请日:1986-08-21

    摘要: Disclosed are 2- and 6-substituted-1-carbadethiapen-2-em-3-carboxylic acids having the structure: ##STR1## wherein R.sup.6, and R.sup.7 are, inter alia, independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl and aralkyl; A is a direct, single bond connecting the indicated S and C atoms, or A is a cyclic or acyclic connecting group selected, inter alia, from alkyl, cyclalkyl, aryl, heteroaryl, heteroalkyl; R.sup.1 and R.sup.2 inter alia, independently selected from hydrogen, alkyl, aryl; additionally, said carbamimidoyl is characterized by cyclic structures achieved by the joinder of the two nitrogen atoms via their substituents and by their joinder to connecting group A; additionally, "carbamimidiums" are disclosed by quarternization of one of the nitrogen atoms of said carbammidoyl. Such compounds as well as their pharmaceutically acceptable salt, ester and amide derivatives are useful as antibiotics. Also disclosed are processes for the preparation of such compounds; pharamaceutical compositions comprising such compounds; and methods of treatment comprising administering such compounds and compositions when an antibiotic effect is indicated.

    摘要翻译: 公开了具有以下结构的2-和6-取代-1-碳代二脱氧-2-烯-3-羧酸:其中R 6和R 7尤其独立地选自氢,烷基,烯基 ,芳基和芳烷基; A是连接所指示的S和C原子的直接的单键,或A是选自烷基,环烷基,芳基,杂芳基,杂烷基的环状或无环连接基团。 R1和R2特别地独立地选自氢,烷基,芳基; 另外,所述的氨基甲脒基的特征在于通过两个氮原子通过它们的取代基并通过它们与连接基团A的连接而实现的环状结构; 此外,“氨基甲酰胺”是通过所述碳酰胺基的氮原子之一的季化来公开的。 这些化合物及其药学上可接受的盐,酯和酰胺衍生物可用作抗生素。 还公开了制备这些化合物的方法; 包含这些化合物的药用组合物; 和治疗方法,包括当指出抗生素效应时施用这些化合物和组合物。